Applied Genetic Technologies Corporation Company Profile (NASDAQ:AGTC)

About Applied Genetic Technologies Corporation (NASDAQ:AGTC)

Applied Genetic Technologies Corporation logoApplied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AGTC
  • CUSIP: N/A
  • Web: www.agtc.com
Capitalization:
  • Market Cap: $73.26 million
  • Outstanding Shares: 18,087,000
Average Prices:
  • 50 Day Moving Avg: $4.02
  • 200 Day Moving Avg: $4.97
  • 52 Week Range: $3.50 - $10.85
P/E:
  • Trailing P/E Ratio: 202.50
  • Foreward P/E Ratio: -2.34
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $39.47 million
  • Price / Sales: 1.86
  • Book Value: $6.38 per share
  • Price / Book: 0.63
Profitability:
  • EBITDA: $2.81 million
  • Net Margins: 4.28%
  • Return on Equity: 1.45%
  • Return on Assets: 1.05%
Debt:
  • Current Ratio: 4.63%
  • Quick Ratio: 4.63%
Misc:
  • Average Volume: 167,651 shs.
  • Beta: 1.63
  • Short Ratio: 1.72
 

Frequently Asked Questions for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

What is Applied Genetic Technologies Corporation's stock symbol?

Applied Genetic Technologies Corporation trades on the NASDAQ under the ticker symbol "AGTC."

How were Applied Genetic Technologies Corporation's earnings last quarter?

Applied Genetic Technologies Corporation (NASDAQ:AGTC) posted its earnings results on Wednesday, September, 13th. The company reported ($0.18) EPS for the quarter, missing the Zacks' consensus estimate of $0.22 by $0.40. The company earned $8.30 million during the quarter, compared to analyst estimates of $12.39 million. Applied Genetic Technologies Corporation had a net margin of 4.28% and a return on equity of 1.45%. The company's quarterly revenue was down 31.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.15 EPS. View Applied Genetic Technologies Corporation's Earnings History.

When will Applied Genetic Technologies Corporation make its next earnings announcement?

Applied Genetic Technologies Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, November, 14th 2017. View Earnings Estimates for Applied Genetic Technologies Corporation.

Where is Applied Genetic Technologies Corporation's stock going? Where will Applied Genetic Technologies Corporation's stock price be in 2017?

7 analysts have issued 1 year price targets for Applied Genetic Technologies Corporation's shares. Their predictions range from $7.00 to $16.00. On average, they expect Applied Genetic Technologies Corporation's share price to reach $11.71 in the next twelve months. View Analyst Ratings for Applied Genetic Technologies Corporation.

What are analysts saying about Applied Genetic Technologies Corporation stock?

Here are some recent quotes from research analysts about Applied Genetic Technologies Corporation stock:

  • 1. Cantor Fitzgerald analysts commented, "Natural history data from imaging 41 patients with CNGB3-associated achromatopsia (ACHM B3) between 6 and 26 months was published in the journel Retina journal today, suggest functional endpoints for evaluating efficacy." (10/6/2017)
  • 2. According to Zacks Investment Research, "Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. Applied Genetic Technologies Corporation is headquartered in Alachua, Florida. " (7/25/2017)
  • 3. Rodman & Renshaw analysts commented, "A leader in AAV development; first-in-man data soon and critical to investment case. AGTC's AAV (adeno-associated virus) platform is based on a proprietary viral composition and manufacturing process that are backed by strong intellectual property positions. AGTC has the capability to target specific tissue types and drive gene expression appropriate for that tissue. We believe that there is great potential to treat an array of disorders that are monogenic (single gene) and autosomal recessive or X-linked. The company is currently targeting orphan ophthalmological indications with the goal of addressing the underlying biology of the disorder.Plenty of cash to fund development. We believe the preclinical data in hand support our projected outcome for positive results from the ongoing clinical programs. We are quickly approaching critical first-in-man data in mid-2017 from the company's lead program in XLRS and initial clinical data from the ACHM program by year-end 2017. We believe these data should help correct the valuation disconnect we call to investors' attention where the stock is trading below the company's cash balance, primarily due to the early stage nature of the platform. Additionally, the company has approximately two years of cash on hand to deliver to our development projections; furthermore, the trajectory should create inflection points that include the clinical data points mentioned as well as advancing more products into development." (3/15/2017)

Who are some of Applied Genetic Technologies Corporation's key competitors?

Who are Applied Genetic Technologies Corporation's key executives?

Applied Genetic Technologies Corporation's management team includes the folowing people:

  • Scott Koenig M.D., Ph.D., Chairman of the Board
  • Susan B. Washer, President, Chief Executive Officer, Director
  • William A. Sullivan, Chief Financial Officer
  • Jeffrey D. Chulay M.D., Senior Vice President, Chief Medical Officer
  • Mark Shearman Ph.D., Chief Scientific Officer
  • Stephen B. Potter, Vice president and chief business officer
  • Andrew D. Ashe, General Counsel
  • Michael H. Goldstein M.D., Chief Medical Officer
  • David R. Guyer M.D., Director
  • Ivana Magovcevic-Liebisch Ph.D. J.D., Director

How do I buy Applied Genetic Technologies Corporation stock?

Shares of Applied Genetic Technologies Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Applied Genetic Technologies Corporation's stock price today?

One share of Applied Genetic Technologies Corporation stock can currently be purchased for approximately $4.05.


MarketBeat Community Rating for Applied Genetic Technologies Corporation (NASDAQ AGTC)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  222 (Vote Outperform)
Underperform Votes:  96 (Vote Underperform)
Total Votes:  318
MarketBeat's community ratings are surveys of what our community members think about Applied Genetic Technologies Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Applied Genetic Technologies Corporation (NASDAQ:AGTC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $11.71 (189.24% upside)
Consensus Price Target History for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
Price Target History for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
Analysts' Ratings History for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017Cantor FitzgeraldSet Price TargetHold$9.00N/AView Rating Details
9/14/2017HC WainwrightReiterated RatingBuy$16.00 -> $8.00HighView Rating Details
9/14/2017BMO Capital MarketsReiterated RatingOutperform$14.00 -> $7.00HighView Rating Details
9/14/2017Stifel NicolausLower Price TargetBuy -> Buy$15.00 -> $12.00HighView Rating Details
3/15/2017Rodman & RenshawInitiated CoverageBuy -> Buy$16.00HighView Rating Details
2/9/2017WedbushReiterated RatingOutperform$15.00N/AView Rating Details
11/9/2016Roth CapitalUpgradeNeutral -> Buy$12.00 -> $15.00N/AView Rating Details
9/26/2016Janney Montgomery ScottUpgradeSell -> Neutral$11.00N/AView Rating Details
9/13/2016Wells Fargo & CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
1/10/2016Chardan CapitalReiterated RatingBuy$25.00N/AView Rating Details
(Data available from 10/22/2015 forward)

Earnings

Earnings History for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
Earnings by Quarter for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
Earnings History by Quarter for Applied Genetic Technologies Corporation (NASDAQ AGTC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017        
9/13/2017Q4 2017$0.22($0.18)$12.39 million$8.30 millionViewN/AView Earnings Details
5/10/2017Q3 2017($0.01)($0.05)$10.39 million$8.39 millionViewN/AView Earnings Details
2/8/2017Q217$0.02$0.11$11.10 million$10.90 millionViewListenView Earnings Details
11/8/2016Q117($0.10)$0.20$10.21 million$11.80 millionViewListenView Earnings Details
9/12/2016Q416$0.07$0.15$13.10 million$12.10 millionViewListenView Earnings Details
5/9/2016Q3$0.05$0.11$12.98 million$12.00 millionViewN/AView Earnings Details
2/8/2016Q216($0.19)$0.17$8.76 million$12.20 millionViewN/AView Earnings Details
11/5/2015Q1($0.20)($0.53)$5.91 million$11.06 millionViewN/AView Earnings Details
9/10/2015Q415($0.41)($0.48)$0.63 million$0.71 millionViewN/AView Earnings Details
5/11/2015Q315($0.33)($0.38)$0.59 million$0.28 millionViewN/AView Earnings Details
2/11/2015Q215($0.39)($0.28)$0.45 million$0.65 millionViewN/AView Earnings Details
11/12/2014Q115($0.29)($0.34)$258.00 million$705.00 millionViewN/AView Earnings Details
9/26/2014Q414($0.29)($0.32)$0.23 million$0.12 millionViewN/AView Earnings Details
5/14/2014Q114($0.37)($25.45)$0.15 million$0.23 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
2017 EPS Consensus Estimate: ($0.36)
2018 EPS Consensus Estimate: ($1.23)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.45)$0.09($0.18)
Q2 20172($0.04)($0.02)($0.03)
Q3 20172($0.14)$0.04($0.05)
Q4 20172($0.16)($0.04)($0.10)
Q1 20181($0.18)($0.18)($0.18)
Q2 20181$0.01$0.01$0.01
Q3 20181($0.35)($0.35)($0.35)
Q4 20181($0.71)($0.71)($0.71)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 54.66%
Insider Trades by Quarter for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
Institutional Ownership by Quarter for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
Insider Trades by Quarter for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/16/2016Ivana MagovcevicDirectorBuy3,000$9.63$28,890.00View SEC Filing  
11/1/2016Jeffrey D ChulayVPSell1,000$7.05$7,050.00View SEC Filing  
9/22/2016Mark S ShearmanInsiderBuy3,000$8.87$26,610.00View SEC Filing  
9/20/2016Stephen W PotterInsiderBuy1,400$8.89$12,446.00View SEC Filing  
9/19/2016Lawrence E BullockCFOBuy10,000$8.75$87,500.00View SEC Filing  
2/23/2015Plc GlaxosmithklineMajor ShareholderSell503,150$22.00$11,069,300.00View SEC Filing  
1/23/2015Daniel L MenichellaVPSell1,996$24.90$49,700.40View SEC Filing  
12/22/2014Daniel L MenichellaVPSell9,000$20.83$187,470.00View SEC Filing  
4/1/2014Interwest Partners Viii LpMajor ShareholderBuy75,376$12.00$904,512.00View SEC Filing  
4/1/2014Jill CarrollDirectorBuy103,762$12.00$1,245,144.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
Latest Headlines for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
Source:
Loading headlines, please wait.

Social

Chart

Applied Genetic Technologies Corporation (AGTC) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.